KNSA Stock Analysis: Buy, Sell, or Hold?
KNSA - Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
$60.94
-2.50 (-3.94%)
▼
5d:
-2.92%
30d:
+23.69%
90d:
+29.44%
BUY
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 04, 2026
20d
Get Alerted When KNSA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: KNSA shows positive signals but monitor for confirmation. Market pricing in 8.6% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: KNSA shows positive signals but monitor for confirmation. Market pricing in 8.6% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$82.88
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$51.46
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: KNSA is currently trading at $60.94, which is considered slightly high relative to its 30-day fair value range of $51.81 to $63.64. From a valuation perspective, the stock is trading at a premium (Forward PE: 35.8) compared to its historical average (27.9). At these levels, the market is pricing in 8.6% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, KNSA is in a strong uptrend. The price is currently testing key support at $59.12. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.9% recently.
Market Sentiment: KNSA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, KNSA is in a strong uptrend. The price is currently testing key support at $59.12. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.9% recently.
Market Sentiment: KNSA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$51.81 -
$63.64
Company Quality Score
65/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
73.1%
All Signals
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.9%)
- NEUTRAL: Near Wall St target ($66.00)
- NEUTRAL: PE elevated vs history but 8.6% growth expectation is conservative given 146% recent growth
Trading Range Analysis
30-Day Trading Range
$51.81 -
$63.64
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
±$3.97
(6.5%)
Support & Resistance Levels
Support Level
$59.12
Resistance Level
$67.53
Current Trend
Strong Uptrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
35.79
Wall Street Target
$66.00
(+8.3%)
Revenue Growth (YoY)
55.5%
Earnings Growth (YoY)
145.5%
Profit Margin
9.7%
Valuation Premium vs History
+8.6% premium
PE vs Historical
35.8 vs 27.9
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+8.6%
(market-implied from PE analysis)
1-Year Target
$66.18
(+9%)
2-Year Target
$71.87
(+18%)
3-Year Target
$78.05
(+28%)
3-Yr Target (if PE normalizes)
(PE: 36→28)
PE COMPRESSION
$60.84
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 35.8, Growth: 46.8%)
$192.66
(+216%)
Base:
(SPY PE: 21.8, Growth: 46.8%)
$117.23
(+92%)
Bear:
(PE: 18.5, Growth: 46.8%)
$99.64
(+64%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (70x PE), but valuation improves significantly next year (36x PE) as earnings recover.
Trailing PE: 69.71 | Current EPS (TTM): $0.91
Bull Case
$130.56
(+114%)
Analyst growth 87.1%, PE expands to 76.7
Base Case
$118.69
(+95%)
Market implied 87.1%, PE stable at 69.7
Bear Case
$43.14
(-29%)
Severe decline -20.0%, PE contracts to 59.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 14, 2026 3:54 AM ET
Data refreshes hourly during market hours. Next update: 4:54 AM
Data refreshes hourly during market hours. Next update: 4:54 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KNSA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
11
Sells
Net
INSIDERS SELLING
Recent Transactions
Ross Moat
SELL
1703 shares
2026-04-09
Michael R Megna
SELL
6625 shares
2026-04-09
Barry D Quart
SELL
6901 shares
2026-04-06
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$198 | 67 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$116 | 59 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$110 | 51 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 55 HOLD |
Advanced KNSA Option Strategies
Professional options setups generated by AI based on today's KNSA price and gamma walls.
